WUXI BIOLOGICS (CAYMAN) INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.66 HKD | +0.55% |
|
+5.01% | -50.47% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 18.16B 2.51B 19.64B | Sales 2025 * | 21.73B 3.01B 23.49B | Capitalization | 56.08B 7.76B 60.64B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.88B 537M 4.2B | Net income 2025 * | 4.92B 681M 5.32B | EV / Sales 2024 * | 2.71 x |
| Net cash position 2024 * | 6.92B 958M 7.48B | Net cash position 2025 * | 7.83B 1.08B 8.47B | EV / Sales 2025 * | 2.22 x |
| P/E ratio 2024 * |
14.9
x | P/E ratio 2025 * |
11.7
x | Employees | 12,740 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.46% |
More Fundamentals
* Assessed data
More news
Latest transcript on WuXi Biologics (Cayman) Inc.
More recommendations
More press releases
More news
| 1 day | +0.41% | ||
| 1 week | +4.87% | ||
| Current month | +6.55% | ||
| 1 month | +2.09% | ||
| 3 months | -6.87% | ||
| 6 months | -70.03% | ||
| Current year | -50.54% |
1 week
14.06
15.10
1 month
12.4215.10
Current year
12.4233.40
1 year
12.4252.45
3 years
12.42148.00
5 years
12.42148.00
10 years
8.33148.00
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 52 | 11-05-31 |
Ming Tu
DFI | Director of Finance/CFO | 54 | 21-08-22 |
Gu Jijie
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jackson Tai
BRD | Director/Board Member | 73 | 23-05-05 |
William Keller
BRD | Director/Board Member | 75 | 17-05-16 |
Ge Li
CHM | Chairman | 56 | 10-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.62% | 0 M€ | -11.74% | - | |
| 4.23% | 0 M€ | +4.72% | - | |
| 3.58% | 1 M€ | -9.86% | - | |
| 2.95% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 14.66 | +0.55% | 60 551 883 |
| 24-05-09 | 14.58 | +3.26% | 64,829,760 |
| 24-05-08 | 14.12 | -2.08% | 35,672,410 |
| 24-05-07 | 14.42 | -2.96% | 43,510,210 |
| 24-05-06 | 14.86 | +6.45% | 87,192,890 |
Delayed Quote Hong Kong S.E., May 10, 2024 at 02:24 am EDT
More quotes
WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
13.47
CNY
Average target price
25.25
CNY
Spread / Average Target
+87.43%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -50.54% | 7.77B | |
| +2.97% | 108B | |
| +10.21% | 104B | |
| +1.57% | 22.33B | |
| -12.77% | 22.19B | |
| -7.05% | 18.69B | |
| -37.64% | 17.74B | |
| -6.50% | 17.64B | |
| +6.00% | 14.05B | |
| +37.20% | 12.51B |
- Stock Market
- Equities
- 2269 Stock